ArticleWorld journal of surgery2012
Prolactin promotes hepatocellular carcinoma through Janus kinase 2.
Article in World journal of surgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Oncogenic driver and therapeutic target: Prolactin signalling axis in retroperitoneal sarcoma.Clinical and translational medicine · 2026Article
- GenPath-PPH: Integrating gene expression and pathway networks via persistent path homology enhances detection of disease-relevant pathways.Computational and structural biotechnology journal · 2025Article
- Investigation of Anti-Liver Cancer Activity of the Herbal Drug FDY003 Using Network Pharmacology.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.BMC cancer · 2021Article
- Article
- A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.Investigational new drugs · 2020Article
- Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.Gastroenterology · 2020Article
- Prolactin Enhances the Proliferation of Proliferative Endometrial Glandular Cells and Endometrial Cancer Cells.Journal of the Endocrine Society · 2020Article
- Hyperprolactinaemia.Journal of clinical medicine · 2019Review
- Domperidone use and risk of primary liver cancer in the Clinical Practice Research Datalink.Cancer epidemiology · 2018Article
- Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice.Scientific reports · 2016Article
- Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma.Oncotarget · 2016Article
- Review
- Integrated analysis of miRNA, gene, and pathway regulatory networks in hepatic cancer stem cells.Journal of translational medicine · 2015Article
- STAT3 activation is required for the antiapoptotic effects of prolactin in cervical cancer cells.Cancer cell international · 2015Article
- Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Identification of serum monocyte chemoattractant protein-1 and prolactin as potential tumor markers in hepatocellular carcinoma.PloS one · 2013Article
- Prolactin and cancer: Has the orphan finally found a home?Indian journal of endocrinology and metabolism · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is one human cancer with obvious gender disparity. This study investigated the association of aberrant prolactin levels with HCC risk and the potential impacts on HCC of the prolactin receptor (PRLR)/Janus kinase 2 (JAK2) signaling.
methodsSerum prolactin of 63 HCC patients and 162 subjects without HCC was measured by radioimmunoassay. The expressions of PRLR and phosphorylated JAK2 (p-JAK2) in 82 retrospectively collected HCC specimens were evaluated by immunohistochemistry and further incorporated into the survival analysis. The immunoblotting and proliferation assays were used to analyze the effects of PRLR/JAK2 signaling on liver cancer cells with prolactin treatment.
resultsSerum prolactin level was significantly higher in HCC patients than in controls. Hepatocellular carcinoma patients with high p-JAK2 expression had a significantly higher postoperative risk than those with low p-JAK2 expression. Moreover, results from the multivariate analysis indicated the prognostic role of p-JAK2 expression with respect to overall survival in HCC patients. In addition, the Kaplan-Meier survival curve showed that high p-JAK2 expression was associated with poor survival in HCC patients with high PRLR expression. The immunoblotting assay showed that prolactin induced the expression of both p-JAK2 and cyclin D1 in Hep-G2 cells. Importantly, the proliferative effects induced by prolactin could be effectively attenuated by adding AG490, a JAK2 inhibitor.
conclusionsIncreased circulating prolactin was found in HCC patients and high p-JAK2 expression could predict poor overall survival in those patients expressing high PRLR. In addition, prolactin contributed to the proliferation of liver cancer cells through PRLR/JAK2 signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.